# Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

Study · id `cardio:ct-nct05598333` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05598333](<https://clinicaltrials.gov/study/NCT05598333>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05598333

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT05598333. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-20 (actual); primary completion 2026-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT05598333, source copy `cardio:ctgov-nct05598333-2025-12-03`, retrieved 2026-10-26)
- Started: 2023-10-20 (actual) (ClinicalTrials.gov record NCT05598333, source copy `cardio:ctgov-nct05598333-2025-12-03`, retrieved 2026-10-26)
- Primary completion: 2026-10-31 (anticipated) (ClinicalTrials.gov record NCT05598333, source copy `cardio:ctgov-nct05598333-2025-12-03`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT05598333, source copy `cardio:ctgov-nct05598333-2025-12-03`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Bulgaria; Canada; Germany; Hungary; Netherlands; Poland; Romania; Spain; United Kingdom (ClinicalTrials.gov record NCT05598333, source copy `cardio:ctgov-nct05598333-2025-12-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05598333-2025-12-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
- Acronym: GenePHIT
- Condition: Congestive Heart Failure
- Intervention (Drug): AB-1002
- Lead sponsor: AskBio Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 39652e33fd0a6577d84c6f4dadf756b3289b80dc6aa50cd3ee603bfe885f425c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
